Status:
COMPLETED
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
Lead Sponsor:
Rabin Medical Center
Conditions:
Hereditary Hemorrhagic Telangiectasia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial. A do...
Detailed Description
Patients with HHT-related epistaxis who will attend our center will randomly be assigned to 6 months of treatment with either Tab. tamoxifen 20 mg once daily or placebo. The group will included both m...
Eligibility Criteria
Inclusion
- Patients suffering from HHT with severe epistaxis
- Over 18 years old
Exclusion
- Under 18 years old
- Pregnancy
- Treatment with anticoagulance
- Treatment with hormones
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00375622
Start Date
February 1 2005
End Date
June 1 2006
Last Update
September 13 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center
Petah Tikva, Israel, 49100